GlassScriptPhysician profile
Tooraj Zahedi
NPI 1083672133
$32,092.35
in general payments reported to CMS, 2019-2025
53 companies · $2,501 in 2025
The $2,501 reported for 2025 was more than what 80% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,291 · 2020: $2,178 · 2021: $4,315 · 2022: $2,662 · 2023: $8,049 · 2024: $7,096 · 2025: $2,501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,000 · Food and Beverage: $8,568 · Travel and Lodging: $66.55 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,000.00 |
| Food and Beverage | $8,568.15 |
| Travel and Lodging | $66.55 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $12,051.43 | 2019-2025 | Afrezza |
| Corcept Therapeutics | $3,736.54 | 2019-2025 | Korlym |
| Abbvie INC. | $2,512.15 | 2019-2025 | Synthroid |
| Novo Nordisk INC | $1,347.11 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $1,212.15 | 2019-2025 | Evenity, Tepezza, Prolia |
| Lilly USA, LLC | $1,144.03 | 2019-2025 | Jardiance, Mounjaro |
| Cequr Corporation | $910.87 | 2022-2025 | Cequr Simplicity |
| Sanofi-Aventis U.S. LLC | $845.90 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $804.60 | 2019-2025 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $505.20 | 2019-2021 | |
| Amarin Pharma, INC. | $494.44 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $477.42 | 2019-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $457.42 | 2021-2024 | |
| Amneal Pharmaceuticals LLC | $441.96 | 2020-2025 | Unithroid |
| Merck Sharp & Dohme LLC | $332.03 | 2019-2022 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $326.15 | 2021-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $325.46 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Ascendis Pharma Endocrinology INC | $319.57 | 2023-2025 | Yorvipath |
| Chiesi USA, INC. | $290.64 | 2024-2025 | Mycapssa |
| Horizon Therapeutics Plc | $280.05 | 2019-2023 | Tepezza |
| Medtronic, INC. | $259.06 | 2021-2025 | Minimed 780g |
| Dexcom, INC. | $257.71 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $257.69 | 2021-2025 | |
| Amryt Pharma Holdings LTD | $246.90 | 2021-2023 | Mycapssa |
| Ibsa Pharma INC. | $244.66 | 2019-2024 | Tirosint, Licart, Tirosint |
| Tandem Diabetes Care, INC. | $195.65 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Vanda Pharmaceuticals INC. | $167.81 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $159.15 | 2019-2022 | |
| Abbott Laboratories | $133.67 | 2021-2024 | Freestyle Libre 3 |
| Pfizer INC. | $128.92 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $124.83 | 2023-2025 | Isturisa, Signifor Lar |
| Medtronic Minimed, INC. | $109.71 | 2019-2020 | |
| Radius Health, INC. | $104.95 | 2019-2024 | Tymlos |
| Astellas Pharma US INC | $98.49 | 2023-2025 | Veozah |
| Shire North American Group INC | $83.23 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.26 | 2020-2021 | |
| Intra-Sana Laboratories | $76.82 | 2023-2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Eisai INC. | $72.00 | 2022-2023 | |
| Becton, Dickinson and Company | $66.24 | 2022 | |
| Vistapharm, INC. | $50.95 | 2021 | |
| Neurocrine Biosciences, INC. | $49.42 | 2024-2025 | |
| Averitas Pharma INC. | $47.63 | 2023-2025 | Qutenza |
| Rhythm Pharmaceuticals, INC. | $39.02 | 2025 | Imcivree |
| Renalytix Ai, INC. | $36.25 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Beta Bionics, INC. | $28.88 | 2024 | Ilet Bionic Pancreas |
| Madrigal Pharmaceuticals | $27.70 | 2025 | Rezdiffra |
| Zealand Pharma US, INC. | $23.90 | 2021 | |
| Esperion Therapeutics, INC. | $22.03 | 2021 | |
| Nevro Corp. | $21.17 | 2021 | |
| Acerus Pharmaceuticals Corporation | $16.97 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.38 | 2021 | |
| Rgh Enterprises LLC | $16.13 | 2025 | |
| Amphastar Pharmaceuticals, INC. | $15.05 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tooraj Zahedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.